title: Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy.
abstract: Sulodexide is a mixed glycosaminoglycan composed of heparin and dermatan sulfate. In this study, the anti-angiogenic effect of sulodexide was investigated using an oxygen-induced retinopathy (OIR) mouse model. The retinas of sham-injected OIR mice (P17) had a distinctive central area of nonperfusion, and this area was significantly decreased in sulodexide-injected mice. The number of neovascular tufts measured by SWIFT_NV and mean neovascular lumen number were significantly decreased in sulodexide-injected mice. Hyperbaric oxygen exposure resulted in increased levels of VEGF, MMP-2 and MMP-9, and when mice were treated with sulodexide, a dose-dependent reduction in VEGF, MMP-2 and MMP-9 levels was observed. Our results clearly demonstrate the anti-angiogenic effect of sulodexide and highlight sulodexide as a candidate supplementary substance to be used for the treatment of ocular pathologies that involve neovascularization.
authors.affiliation: Functional Food Center, Korea Institute of Science and Technology (KIST) Gangneung Institute, Gangneung 210-340, Korea.
authors.forename: Hyoung
authors.initials: H
authors.lastname: Jo
authors.affiliation: Functional Food Center, Korea Institute of Science and Technology (KIST) Gangneung Institute, Gangneung 210-340, Korea.
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Jung
authors.affiliation: Department of Pathology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, Korea.
authors.forename: Jun
authors.initials: J
authors.lastname: Kang
authors.affiliation: Department of Ophthalmology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, Korea.
authors.forename: Hye Bin
authors.initials: HB
authors.lastname: Yim
authors.affiliation: Department of Ophthalmology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, Korea.
authors.forename: Kui Dong
authors.initials: KD
authors.lastname: Kang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D016650:Fluorescein-5-isothiocyanate / Q000737:chemistry / Q000378:metabolism; D006025:Glycosaminoglycans / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D010100:Oxygen / Q000633:toxicity; D012160:Retina / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced / Q000628:therapy*; D015861:Retinal Neovascularization / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D006025:Glycosaminoglycans; D042461:Vascular Endothelial Growth Factor A; C007858:glucuronyl glucosamine glycan sulfate; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D016650:Fluorescein-5-isothiocyanate; D010100:Oxygen